



Press Release

FOR IMMEDIATE RELEASE

Contacts: Patricia Vaccarino,
Managing Partner
Xanthus Communications
(206) 979 3380
patricia@xanthuscom.com

Elizabeth Suman,
Media Analyst
Xanthus Communications
(206) 718 0913
elizabeth@xanthuscom.com

The Healionics Corporation announces an important partnership with BioMimetic Tissue Sciences.

***Partnership has the potential to help dogs that suffer
from glaucoma—the leading cause of blindness.***

Redmond, WA, July 24th 2007— Today the Healionics Corporation announced a partnership deal with BioMimetic Tissue Sciences, a company focused on using biomaterials for veterinary purposes. The partnership between Healionics and BioMimetic Tissue Sciences will initially focus on ophthalmic devices in canine glaucoma. The results of the partnership have the potential to offer relief to dogs that suffer from glaucoma. Glaucoma, the leading cause of blindness in dogs, presents a challenge to dog owners and veterinarians.

Dr. Craig Woods, Veterinarian and CEO of BioMimetic Tissue Sciences, said, “We are pleased to be working with the Healionics Corporation on this exciting project. The ophthalmic device will be optimized for canine patients and should permit enhanced tissue integration and filtration of excess fluid. If successful, this device would be a substantial advancement in veterinary ophthalmology and help thousands of dogs each year.”

The Washington-based Healionics Corporation is leveraging its portfolio of intellectual property, which has been licensed from the University of Washington (UW) and sub-licensed from the Ratner Biomedical Group. This portfolio includes STAR material (Sphere Templated Angiogenic Regenerative), which works with the body to promote healing and to prevent rejections from the human body’s natural tendency to fight implanted medical devices as if they were foreign bodies.

According to Healionics COO Michel Alvarez, "We appreciate BioMimetic's interest in advancing our flagship STAR biomaterial scaffold technology for potential use in veterinary ophthalmic device applications. Moreover, this provides a nice stepping-stone for potential STAR material applications in the human ophthalmic device market."

Ophthalmic devices are just one of the many potential applications in a wide range of healthcare markets that are potentially compatible with Healionics' versatile STAR material. Healionics currently has several other partnership deals that are being negotiated and will soon be announced.

Earlier this year the Healionics Corporation received an initial round of funding and was the first company to spin off from the Ratner Biomedical Group. CEO Robert Brown leads the Healionics Corporation. Other members of the Healionics Management team include Chief Technology Officer Dr. Max Maginness and Chief Operating Officer Michel Alvarez. Dr. Buddy D. Ratner is Director of Healionics' Scientific Advisory Board and Christopher Somogyi is Chairman of the Healionics Board of Directors. The Healionics Corporation office and lab is located at 14787 NE 95th Street, Building B, in Redmond, WA 98052.

About Healionics Corporation

Healionics is a biomaterials company whose mission is to partner with medical device manufacturers to enhance the biocompatibility and performance of current and next-generation devices in order to dramatically reduce deaths that are related to biocompatibility issues. Healionics utilizes its portfolio of intellectual property to create products and solutions that enhance and increase the quality of life. Healionics has licensed **STAR Material** – Sphere Templated Angiogenic Regenerative Material. (STAR) material is a paradigm shift in biocompatibility because it works with the body to promote healing. STAR material also enables the biocompatibility of a wide range of medical devices that are implanted into the body. The Healionics management team is composed of CEO and Director Robert Brown, COO Michel Alvarez, and CTO Dr. Max Maginness. Dr. Buddy D. Ratner currently serves as chair of the SAB for Ratner BioMedical Group and the Healionics SAB. Christopher Somogyi currently serves as Chairman of the Board of Directors for Ratner Biomedical Group and the Healionics Corporation. For more information, please see <http://www.healionicscorp.com> or contact +1 425. 818.1987 or info@healionicscorp.com.

About BioMimetic Tissue Sciences™

TR BioSurgical, LLC, founded in May 2007, is a veterinary biomedical development company located in Scottsdale, Arizona. Doing business as BioMimetic Tissue Sciences (BTS), the company was founded by a group of veterinarians, scientists and business professionals in an effort to identify, develop and commercialize the most promising biomaterial technologies for veterinary medicine. BTS has exclusive worldwide animal health options for several novel technology platforms, including the BTS-BioGEL™ copolymer technology. For more information about BTS, please visit <http://www.btsciences.com> or contact Craig Woods cwoods@btsciences.com